XtalPi Inc. (2228.HK) and Hangzhou Baicheng Medicine Technology Co., Ltd. (301096.SZ) today announced the signing of a Letter of Intent (LOI) to establish a strategic partnership. Under the terms of the LOI, Baicheng Medicine will engage XtalPi to leverage its cutting-edge “AI + Robotics” platform for novel drug discovery, while XtalPi will commission Baicheng Medicine to conduct pharmaceutical research and related development activities.
The collaboration aims to address unmet clinical needs in multiple therapeutic areas, including pain management, narcolepsy, oncology, autoimmune diseases, and ophthalmology. By harnessing XtalPi’s AI-driven drug discovery platform, the two companies will jointly advance the development and incubation of innovative drug pipelines. Additionally, they plan to explore the establishment of a joint venture to expand commercial opportunities in broader domains. The proposed transactions under the LOI are subject to further negotiations and the execution of definitive, legally binding agreements.
Baicheng Medicine brings a seasoned team of experts in innovative drug development, with robust capabilities spanning target identification to global commercialization. The company has established a comprehensive ecosystem for drug discovery, development, manufacturing, and regulatory registration, positioning it as a leader in pharmaceutical innovation.
